AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Things get a little nerdy in this episode, which focuses on the basic science of what makes the inflammasome tick in CAPS, as well as data on the use of interleukin 1 inhibition. Hint: Listen to “The Inflammasome for Dunces” episode first, and this one will make more sense.
Brought to you by GSK. Considering a treatment change for patients with active SLE? Learn about a treatment option for your patients at treatfortodayandtomorrow.com
We’d love to hear from you! Send your comments/questions to rheuminationspodcast@healio.com. Follow us on Twitter @HRheuminations @AdamJBrownMD @HealioRheum
Brought to you by GSK. Consider the long-term impact of disease activity, flares and corticosteroid use on patients with active SLE. Learn more now at treatfortodayandtomorrow.com.
Disclosure: Brown reports no relevant financial disclosures.
References:
Agostini L, et al. Immunity. 2004;20:319-325.
Brogan PA, et al. Arthritis Rheum. 2019;71:1955-1963.
Marsaud C, et al. J Rheumatol. 2014;41:1721-1722.
Hawkins PN, et al. NEJM. 2003;348:2583-2584.
Hoffman HM, et al. Lancet. 2004;364:1779-1785.
Hoffman HM, et al. Clin Ther. 2012;34:2091-2103.
Ito S, et al. Arthritis Res Ther. 2014;16:doi:10.1186/ar4483.
Kuemmerle-Deschner JB, et al. Ann Rheum Dis. 2011;70:2095-2102.
Lachmann HJ, et al. NEJM. 2009;360:2416-2425.
Mamoudjy N, et al. Orphanet J Rare Dis. 2017;12:doi:10.1186/s13023-017-0589-1.
Rosengren S, et al. J Allergy Clin Immunol. 2007;119:991-996.
Ross JB, et al. J Cutan Med Surg. 2008;12:8-16.